Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy - PubMed (original) (raw)
Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy
S Armando Villalta et al. Hum Mol Genet. 2009.
Abstract
Duchenne muscular dystrophy (DMD) is the most common, lethal, muscle-wasting disease of childhood. Previous investigations have shown that muscle macrophages may play an important role in promoting the pathology in the mdx mouse model of DMD. In the present study, we investigate the mechanism through which macrophages promote mdx dystrophy and assess whether the phenotype of the macrophages changes between the stage of peak muscle necrosis (4 weeks of age) and muscle regeneration (12 weeks). We find that 4-week-old mdx muscles contain a population of pro-inflammatory, classically activated M1 macrophages that lyse muscle in vitro by NO-mediated mechanisms. Genetic ablation of the iNOS gene in mdx mice also significantly reduces muscle membrane lysis in 4-week-old mdx mice in vivo. However, 4-week mdx muscles also contain a population of alternatively activated, M2a macrophages that express arginase. In vitro assays show that M2a macrophages reduce lysis of muscle cells by M1 macrophages through the competition of arginase in M2a cells with iNOS in M1 cells for their common, enzymatic substrate, arginine. During the transition from the acute peak of mdx pathology to the regenerative stage, expression of IL-4 and IL-10 increases, either of which can deactivate the M1 phenotype and promote activation of a CD163+, M2c phenotype that can increase tissue repair. Our findings further show that IL-10 stimulation of macrophages activates their ability to promote satellite cell proliferation. Deactivation of the M1 phenotype is also associated with a reduced expression of iNOS, IL-6, MCP-1 and IP-10. Thus, these results show that distinct subpopulations of macrophages can promote muscle injury or repair in muscular dystrophy, and that therapeutic interventions that affect the balance between M1 and M2 macrophage populations may influence the course of muscular dystrophy.
Figures
Figure 1.
Th1 and Th2 responsive macrophages that express markers of M1 or M2 phenotype are present in mdx muscle. Cross-sections of 4-week-old mdx mouse quadriceps were immunolabeled with rat anti-mouse F4/80 to identify macrophage populations (A and D). The expression of iNOS (B) and CD206 (E), markers of classical and alternative activation, respectively, were simultaneously assayed by double immunofluorescence staining to determine the activation state of macrophages. Superimposed images demonstrate that macrophages undergo classical, M1 (C) and alternative, M2 activation (F) in mdx dystrophic muscle. Scale bar: 50 µm. Macrophages in mdx muscle express receptors for IFNγ and IL-4, suggesting that their activation may occur through IFNγ and IL-4-mediated signaling. Cross-sections of 4-week-old C57 (G, J) and mdx (H, I, K and L) quadriceps were immunohistochemically stained to determine the tissue distribution of IFNγR1 and IL-4R. Red reaction products, reflecting IFNγR1 (H) and IL-4R (K) expression, were noted in inflammatory cells present in necrotic lesions of mdx quadriceps, but absent in C57 quadriceps (G, J). Labeling of adjacent cross-sections with antibodies against F4/80 indicated that IFNγR1 and IL-4R-expressing cells were macrophages (I, L). Scale bar: 50 µm.
Figure 2.
Macrophages isolated from mdx muscle express iNOS and arginase-1, further supporting the conclusion that M1 and M2a macrophages are present in mdx muscle. Western blot shows that IFNγ induces iNOS expression in mdx muscle macrophages, which is further increased with the addition of TNFα (A, top panel). However, IL-4 reduced the expression of iNOS protein by mdx muscle macrophages (A, top panel). IFNγ reduced arginase-1 expression, while IL-4 or IL-10 increased arginase-1 expressed by mdx muscle macrophages (A, bottom panel). Representative blots from 3 to 4 independent experiments are shown. The treatment of muscle macrophages with IL-4 further decreased iNOS expression with time, and a greater repression was observed when IL-4 was used together with IL-10 (B, top panel). IL-4 treatment of muscle macrophages maximally induced arginase-1 expression by 24 h (B, bottom panel). However, arginase-1 expression was further induced by IL-4 in the presence of IL-10 with levels peaking by 48 h (B, bottom panel).
Figure 3.
Classically activated macrophages mediate muscle cell lysis via an NO-dependent mechanism. Cytotoxicity assays showed that M1 peritoneal (left panel, PMΦ) and mdx muscle macrophages (right panel, MMΦ) had the highest cytotoxic activity (A). *, P < 0.05 when compared with non-stimulated control at the same concentration. #, P < 0.05 when compared with macrophages cultured at 6250 MΦ/mm2 within the same treatment condition. τ, P < 0.05 when compared with macrophages cultured at 6250 and 12 500 MΦ/mm2 within the same treatment condition. The increase in muscle cells lysis mediated by M1 muscle macrophages paralleled increases in iNOS expression when they were cocultured with myotubes (B). Cytotoxicity assays performed in the presence of L-NAME showed that inhibition of NO synthesis resulted in a dose-dependent decrease in muscle cell lysis mediated by M1 peritoneal and muscle macrophages (C). *, P < 0.05 when compared with M1. #, P<0.05 when compared with M1 treated with 50 µM L-NAME. Non, non-stimulated macrophages; M1, M1 macrophages; M2a, M2a macrophages; PR, nitrocellulose membranes stained with ponceau red to ensure equal loading of total protein. Representative histograms or blots of 2–3 independent experiments are shown.
Figure 4.
Null mutation of iNOS reduces muscle membrane lysis in mdx muscles. (A) Intracellular fluorescence of procion orange treated muscles was used as an index of muscle fiber membrane damage. The peaks show the aggregate data for all fibers in cross-sections of the entire soleus muscle from all mice in each treatment group. The leftward shift of peaks on the abscissa indicates a decrease in fibers with membrane lesions in the iNOS null/mdx muscles, compared with iNOS expressing mdx. Background fluorescence set at intensity=0 was determined by measuring fluorescence at a region of the section where there was no tissue. (B and C) Null mutation of iNOS did not significantly affect the numbers of macrophages or neutrophils in mdx muscles at 4 or 12 weeks of age. However, ablation of iNOS caused a significant reduction in the percentage of muscle fibers that were regenerative, central-nucleated fibers. Bars=sem. *, P < 0.05 when compared with age-matched, iNOS-expressing mdx. #, P < 0.05 when compared with 4-week-old mice of the same genotype. (D) Western blotting for iNOS confirmed that iNOS was expressed in mdx muscle extracts, and that no iNOS protein expression was detectble in the double-mutant mouse muscles.
Figure 5.
M2 macrophages inhibit muscle cell lysis by M1 macrophages via an arginase-1 dependent mechanism. Cytotoxicity assays showed that M1 and M2 peritoneal macrophage cocultures resulted in a 17% reduction in myotube lysis when compared with M1 only cultures (A). In contrast, coculturing M1 macrophages with non-stimulated peritoneal macrophages resulted in a 17% increase in myotube lysis when compared with M1 only cultures (A). Measurements of nitrite showed that the reduction of muscle cell lysis observed in M1:M2 cocultures was attributed to reduced nitrite levels (B) and occurred without a reduction in iNOS protein (C). Cytotoxicity assays performed in the presence of BEC showed that inhibition of arginase activity resulted in a dose-dependent increase in nitrite formation (D) and muscle cell lysis (E) in M1:M2 cocultures compared with non-treated macrophage:M2 cocultures. *, P < 0.05 when compared with M1 only cultures. ♦, P < 0.01 when compared with non-treated macrophage:M1 cocultures. §, P < 0.05 when compared with non-treated M1:non-coculture. #, P < 0.01 when compared with same coculture conditions not treated with BEC. £, P < 0.01 when compared with same coculture condition treated with 1 µM BEC. τ, P < 0.05 when compared with same coculture condition treated with 10 µM BEC. Representative histograms of 2–5 independent experiments are shown.
Figure 6.
M1 macrophages in mdx muscle undergo deactivation as the disease progresses from the acute peak of pathology (4-weeks-old) to the regenerative phase of the disease (12 weeks). Cytotoxicity assays showed that macrophages isolated from 4-week-old mdx muscle are more cytolytic in vitro compared with macrophages isolated at 12 weeks (A). A representative of three independent experiments is shown. The greater cytotoxicity of 4-week-old macrophages correlated with higher expression levels of iNOS protein (B). The elevated levels of iNOS at 4 weeks are partly attributed to increased expression of STAT-1, which leads to increased levels of STAT-1 activation (phosphorylated STAT-1, B). Measurements of IFNγ by real-time PCR showed that it was elevated in mdx hamstrings but did not differ significantly between 4 and 12 weeks (C, left panel). Transcript levels of IL-4 were upregulated in 12-week-old mdx hamstrings (C, right panel). Representative histograms of two independent experiments are shown. Consistent with the increased expression of IL-4, genes associated with alternative activation increased in 12-week-old mdx hamstrings relative to 4-week-old mdx hamstrings (D). Measurements of genes associated with classical activation showed a downward trend of expression in 12-week-old mdx hamstrings relative to 4-week-old mdx hamstrings (D, top panel). *, P < 0.05, relative to age-matched control. #, P < 0.05, relative to 4-week-old mdx. τ, P < 0.01, relative to 4-week-old mdx. ♦, P < 0.01, relative to C2C12 cultures grown without macrophages (C2C12 only).
Figure 7.
Summary diagram of the macrophage phenotypes that dominate the acute necrotic phase and the regenerative phase of mdx muscular dystrophy. Muscle in the acute necrotic phase of the disease contains iNOS-expressing, M1 macrophages that are capable of lysing muscle fibers by NO-mediated cytotoxicity, and arginase-expressing M2a macrophages that compete with iNOS for arginine, which can thereby reduce M1 macrophage cytotoxicity. As mdx mice enter the regenerative phase, there is an increase in IL-10 expression that accompanies deactivation of the M1 and M2a phenotypes, reflected in a reduction in iNOS and arginase expression. Macrophages in regenerative muscle resemble an M2c population in which cytotoxicity is low, and the production of anti-inflammatory cytokines (IL-10, IL-1, IL-1Ra) are elevated, but arginase expression is greatly reduced.
Similar articles
- Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype.
Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Villalta SA, et al. Hum Mol Genet. 2011 Feb 15;20(4):790-805. doi: 10.1093/hmg/ddq523. Epub 2010 Nov 30. Hum Mol Genet. 2011. PMID: 21118895 Free PMC article. - IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation.
Villalta SA, Deng B, Rinaldi C, Wehling-Henricks M, Tidball JG. Villalta SA, et al. J Immunol. 2011 Nov 15;187(10):5419-28. doi: 10.4049/jimmunol.1101267. Epub 2011 Oct 17. J Immunol. 2011. PMID: 22013114 Free PMC article. - Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.
Wehling-Henricks M, Jordan MC, Gotoh T, Grody WW, Roos KP, Tidball JG. Wehling-Henricks M, et al. PLoS One. 2010 May 21;5(5):e10763. doi: 10.1371/journal.pone.0010763. PLoS One. 2010. PMID: 20505827 Free PMC article. - Regulatory interactions between muscle and the immune system during muscle regeneration.
Tidball JG, Villalta SA. Tidball JG, et al. Am J Physiol Regul Integr Comp Physiol. 2010 May;298(5):R1173-87. doi: 10.1152/ajpregu.00735.2009. Epub 2010 Mar 10. Am J Physiol Regul Integr Comp Physiol. 2010. PMID: 20219869 Free PMC article. Review. - Regulatory T cells and skeletal muscle regeneration.
Schiaffino S, Pereira MG, Ciciliot S, Rovere-Querini P. Schiaffino S, et al. FEBS J. 2017 Feb;284(4):517-524. doi: 10.1111/febs.13827. Epub 2016 Aug 18. FEBS J. 2017. PMID: 27479876 Review.
Cited by
- Changes in Type 1 Diabetes-Associated Gut Microbiota Aggravate Brain Ischemia Injury by Affecting Microglial Polarization Via the Butyrate-MyD88 Pathway in Mice.
Zeng X, Ma C, Fu W, Xu Y, Wang R, Liu D, Zhang L, Hu N, Li D, Li W. Zeng X, et al. Mol Neurobiol. 2024 Sep 26. doi: 10.1007/s12035-024-04514-9. Online ahead of print. Mol Neurobiol. 2024. PMID: 39322832 - Frequent Icing Stimulates Skeletal Muscle Regeneration Following Injury With Necrosis in a Small Fraction of Myofibers in Rats.
Kawashima M, Nagata I, Terada E, Tamari A, Kurauchi M, Sakuraya T, Sonomura T, Oyanagi E, Yano H, Peake JM, Arakawa T. Kawashima M, et al. J Histochem Cytochem. 2024 Aug-Sep;72(8-9):569-584. doi: 10.1369/00221554241274882. Epub 2024 Sep 6. J Histochem Cytochem. 2024. PMID: 39240248 - LED therapy modulates M1/M2 macrophage phenotypes and mitigates dystrophic features in treadmill-trained mdx mice.
Pereira VA, da Silva HNM, Fernandes EM, Minatel E. Pereira VA, et al. Photochem Photobiol Sci. 2024 Sep;23(9):1735-1747. doi: 10.1007/s43630-024-00626-2. Epub 2024 Sep 4. Photochem Photobiol Sci. 2024. PMID: 39227554 - Spatiotemporal transcriptomic mapping of regenerative inflammation in skeletal muscle reveals a dynamic multilayered tissue architecture.
Patsalos A, Halasz L, Oleksak D, Wei X, Nagy G, Tzerpos P, Conrad T, Hammers DW, Sweeney HL, Nagy L. Patsalos A, et al. J Clin Invest. 2024 Aug 27;134(20):e173858. doi: 10.1172/JCI173858. J Clin Invest. 2024. PMID: 39190487 Free PMC article. - Failure to Resolve Inflammation Contributes to Juvenile-Onset Cardiomyopathy in a Mouse Model of Duchenne Muscular Dystrophy.
Novak JS, Lischin A, Uapinyoying P, Hindupur R, Jae Moon Y, Bhattacharya S, Tiufekchiev S, Barone V, Mázala DAG, Gamu IH, Walters G, Panchapakesan K, Jaiswal JK. Novak JS, et al. bioRxiv [Preprint]. 2024 Aug 15:2024.08.15.607998. doi: 10.1101/2024.08.15.607998. bioRxiv. 2024. PMID: 39185176 Free PMC article. Preprint.
References
- Hoffman E.P., Brown R.H., Jr, Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928. - PubMed
- Tidball J.G., Wehling-Henricks M. Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr. Res. 2004;56:831–841. - PubMed
- Hodgetts S., Radley H., Davies M., Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul. Disord. 2006;16:591–602. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AR47721/AR/NIAMS NIH HHS/United States
- R01 AR047721/AR/NIAMS NIH HHS/United States
- R01 AR40343/AR/NIAMS NIH HHS/United States
- R01 AR047855/AR/NIAMS NIH HHS/United States
- F31 AR054724/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous